We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

103 hedge funds and large institutions have $158M invested in Atea Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 36 increasing their positions, 37 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 37

3% less funds holding

Funds holding: 106 → 103 (-3)

4.8% less ownership

Funds ownership: 66.7% → 61.9% (-4.8%)

16% less capital invested

Capital invested by funds: $189M → $158M (-$30.4M)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

48% less call options, than puts

Call options by funds: $23K | Put options by funds: $44K

Holders
103
Holders Change
-3
Holders Change %
-2.83%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
8
Increased
36
Reduced
37
Closed
11
Calls
$23K
Puts
$44K
Net Calls
-$21K
Net Calls Change
+$119K

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.14M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$644K
3
CM
CM Management
Florida
+$624K
4
PLC
Peapod Lane Capital
New York
+$385K
5
BCM
Bridgeway Capital Management
Texas
+$343K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$11.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.27M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$851K
4
Citadel Advisors
Citadel Advisors
Florida
-$614K
5
BlackRock
BlackRock
New York
-$372K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$773K -$167K -53,527 -17%
Two Sigma Investments
27
Two Sigma Investments
New York
$753K -$107K -34,172 -12%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$607K -$27.8K -8,914 -4%
HSBC Holdings
29
HSBC Holdings
United Kingdom
$604K +$122K +39,023 +24%
AI
30
Auour Investments
Massachusetts
$522K – – –
Invesco
31
Invesco
Georgia
$518K -$73.5K -23,546 -12%
Barclays
32
Barclays
United Kingdom
$512K -$89.9K -28,801 -14%
American Century Companies
33
American Century Companies
Missouri
$487K +$55.1K +17,666 +12%
BCM
34
Bridgeway Capital Management
Texas
$428K +$343K +109,800 +330%
AllianceBernstein
35
AllianceBernstein
Tennessee
$356K – – –
Jacobs Levy Equity Management
36
Jacobs Levy Equity Management
New Jersey
$353K -$851K -272,732 -70%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$348K -$41.7K -13,353 -10%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$316K +$169K +54,027 +105%
SO
39
STRS Ohio
Ohio
$315K – – –
Jane Street
40
Jane Street
New York
$307K +$143K +45,716 +80%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$293K -$55.8K -17,873 -15%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$252K -$37.7K -12,072 -13%
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$239K +$18.8K +6,027 +8%
Millennium Management
44
Millennium Management
New York
$229K +$169K +54,056 +240%
HighTower Advisors
45
HighTower Advisors
Illinois
$225K +$78K +25,001 +50%
Macquarie Group
46
Macquarie Group
Australia
$209K – – –
UBS Group
47
UBS Group
Switzerland
$190K -$29.2K -9,345 -13%
SC
48
Shay Capital
New York
$183K +$95.2K +30,491 +100%
Bank of America
49
Bank of America
North Carolina
$181K -$39.9K -12,780 -17%
Deutsche Bank
50
Deutsche Bank
Germany
$180K +$188K +60,263 New
1
2
3 4 5

AVIR Hedge Fund Activity: Q1 2025 in Review

103 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2025, worth a combined $158M — down 16% from $189M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of AVIR and 8 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 36 added.

The largest buyer was JP Morgan Chase, adding an estimated $1.14M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $11.2M sold.

  • 103 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2025, down from 106 in Q4 2024.
  • Funds reported $158M of Atea Pharmaceuticals stock for Q1 2025, down 16% quarter-over-quarter.
  • 8 funds opened new Atea Pharmaceuticals positions in Q1 2025 and 11 closed out, a net change of -3 holders.
  • The largest Atea Pharmaceuticals buyer in Q1 2025 was JP Morgan Chase, an estimated $1.14M added.
  • The largest Atea Pharmaceuticals seller in Q1 2025 was EcoR1 Capital, an estimated $11.2M sold.

Based on aggregated 13F filings for Q1 2025.